Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I read somewhere that LL in conjunction with other cancer therapies amplifies their effectiveness by two orders of magnitude.
31.7 million shares sold short
Some have speculated an $80 per share deal paid for in the acquiring company’s stock like J&J for example.
We will see how well that post ages over time.
I completely agree.
Thanks!
Published half-life for HIV treatment is 3.4 to 3.7 days. Where did the 7 to 10 days that is being discussed come from?
$2.97 in Stuttgart
CytoDyn’s #Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients :: CytoDyn Inc. (CYDY). Leronlimab might be the best immunomodulator @Medscape @nejm https://t.co/T2yjCdGCDM
— Abu Shoyeb, MD (@abushoyeb) March 31, 2021
$cydy broke above middle Bollinger band with RSI still.oversold at 39. Has room to fill the gap and test 200 day sma at 4.00.
— Friar Tuck (@tomyarborough) March 30, 2021
It’s all about understanding “half-life”, how the drug spends. If CD12 dosage hadn’t been capped a lot of those over 65 patients would be alive today. Geez, let the doctors practice real medicine and treat their patients. Obviously the case study of that patient recovering with 4 doses after 84 days on ECMO made them look carefully at the CD12 data again.
Nice to see buying volume increase. We should hear something about long-hauler trial soon.
CDC director Walenski needs to be educated about what Leronlimab can do.
https://www.c-span.org/video/?509827-1/senate-committee-hearing-covid-19-pandemic-response
Excellent and scathing. Tomorrow Our therapeutic, superior to HGEN’ s will be on day #18 after formal application for EUA.
CDC need to get their thumb out of their ass and advocate for Leronlimab with the FDA. We have a stockpile.
Looks like HGEN CEO has a gift for shareholders after lubricating them with some spun clinical trial results.
https://www.businesswire.com/news/home/20210329005744/en/Humanigen-Announces-Proposed-Public-Offering-Million-Shares
CYDY +14.3% in Stuttgart so far.
Dr. John Bream, from the front lines in the fight against COVID19, offers his heartfelt testimony. Patients in desperate final stage condition across the world would have a 24-40% better chance of survival once Leronlimab is approved.
Dr. Bream is among a growing chorus of voices urging the FDA to speed approval of this life-saving drug. Phase 3 trials demonstrate impressive efficacy well beyond other drugs that were approved but are not nearly as effective. The safety record of Leronlimab is still flawless after six year of regular use on HIV patients.
An estimated 40% more patients on ventilators would survive through the use of CytoDyn's Leronlimab and hospital stays have been found to average six fewer days.
Each day that passes puts more people at risk by holding back on a timely approval, especially since safety is clearly not an issue. Six fewer days at $25,000 per day, saves tremendously on costs and healthcare resources - significantly impacting the availability of hospital beds.
FDA Director, Dr. Woodcock, should wave the three month trial being done only to very slightly increase the p-value. We are in a pandemic and many lives could be saved by acting now.
Dr. Woodcock herself is famous for asking the rhetorical questions, "Would you risk your own life to raise a p-value?" Please take your own oh-so-obvious advice and move forward with the approval a soon as is humanly possible.
They need to see this in Portuguese
— Chris Johnson (@ChrisJo74235525) March 15, 2021
Lenslosermab! No match for Leronlimab.
Video removed
Correct!
Let this sink in—
— Eric Feigl-Ding (@DrEricDing) March 27, 2021
The more contagious #P1 variant from Brazil has now invaded N America—British Columbia🇨🇦 has a sudden cluster of 215+ new #P1 cases sequenced by one Vancouver lab.#P1 is more contagious, has reinfection risk and possibly more severe.🧵pic.twitter.com/CKGI3umuk5
Great post!
Absolutely, and it is the point of scientific clinical investigations. Adding to that CYDY has unquestionably saved MANY lives.
If I am not mistaken, an Osteopath is required to take an additional year in Medical School.
Which is the boba fide lawsuit?
31.7 million shares short now.
23.2k stacked up on the ask @ $2.17.
This patient was given 4 weeks worth of Leronlimab instead the the 2 weeks like in the CD-12 trial. Seems like Dr. L was right on the money when he said the results of CD12 would have been earth shattering if the trial wasn’t capped at 2 shots.
Why can’t they do that in OLE or a phase 4 with an EUA to prove it? Would any of our real medical professionals care to comment on this???
What about real experimental design? Three data points minimum on each variable?
As they say, “If you think real professional help is too expensive, just try hiring an amateur and you’ll change your mind”
I did some research on Amarex on LinkedIn, and I wasn’t impressed.